Botox Alternatives Compared
| Botox (onabotulinumtoxinA) | Aimovig (erenumab) | Qulipta (atogepant) |
|
|---|
| Botox (onabotulinumtoxinA) | Aimovig (erenumab) | Qulipta (atogepant) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Botox is approved to treat many conditions, such as chronic migraine, involuntary muscle contractions or twitching, excessive sweating, increased saliva, and overactive bladder to name a few. Botox... View more |
Prescription only
Aimovig is a prescription medicine that can be self-injected under the skin once a month to prevent migraine headaches in adults. Injection site reactions and constipation are the most common side... View more |
Prescription only
Prescribed for Chronic Migraine, Migraine Prevention. Qulipta may also be used for purposes not listed in this medication guide. |
Related suggestions Migraine Prevention (Migraine Prophylaxis)
|
|||||||||||||||||||||||
| More about Botox (onabotulinumtoxinA) | More about Aimovig (erenumab) | More about Qulipta (atogepant) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Botox has an average rating of 5.7 out of 10 from a total of 472 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 42% reported a negative effect. |
Aimovig has an average rating of 5.2 out of 10 from a total of 641 ratings on Drugs.com. 38% of reviewers reported a positive effect, while 44% reported a negative effect. |
Qulipta has an average rating of 8.1 out of 10 from a total of 171 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 8% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Botox side effects |
View all Aimovig side effects |
View all Qulipta side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Botox prices |
View all Aimovig prices |
View all Qulipta prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other onabotulinumtoxinA brands include: Botox Cosmetic |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
672 hours |
11 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 120 drugs are known to interact with Botox:
|
A total of 2 drugs are known to interact with Aimovig:
|
A total of 190 drugs are known to interact with Qulipta:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
December 09, 1991 |
May 17, 2018 |
September 28, 2021 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.